Tuesday, 28 February 2017

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

ResearchMoz added Latest Research Report titled " Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation " to it's Large Report database.

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3–1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=799450

  • Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.
  • What is the pathophysiology of RA?
  • Which products and therapeutic strategies dominate the clinical and commercial landscapes?
  • What are the most significant unmet needs within the RA market?
  • Considerable diversification from current market trends is evident within the RA pipeline.
  • Which molecular targets are most prominent within the pipeline?
  • What proportion of pipeline products are first in class?
  • Which first-in-class targets are most promising?
  • Deal values for licensing and co-development deals vary considerably.
  • How many strategic consolidations have been completed in the past decade?
  • Which types of assets attract the largest deal values?
  • Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining 5
2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation 5
2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products 5

3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Development Remains Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 9
3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Disease Symptoms 10
4.3 Epidemiology 11
4.4 Etiology 11
4.5 Pathophysiology 11
4.6 Co-morbidities and Complications 12
4.7 Diagnosis 12
4.7.1 Blood Tests 12
4.7.2 1987 Rheumatoid Arthritis Classification 13

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

No comments:

Post a Comment